SCHEMBL18317813

SCHEMBL18317813

Nc1ccc(C=CC(=O)NCc2cc3cc(-c4ccc(C(=O)N5CCC(F)(F)CC5)cn4)c(C(F)(F)F)cc3o2)cn1

nearest known ligand 0.67

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ PAK4 O96013 2/20 0.67
▸ NAMPT P43490 2/20 0.61
▸ PAK1 Q13153 1/20 0.61
▸ HRH3 Q9Y5N1 10/20 0.35
▸ GPR183 P32249 4/20 0.34
▸ STAT3 P40763 1/20 0.34
▸ PIK3CG P48736 1/20 0.33
▸ PIK3R5 Q8WYR1 1/20 0.33
▸ RORC P51449 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29611224 1.00 PAK4 (0.67) PAK4NAMPTPAK1HRH3GPR183
SCHEMBL16345818 1.00 PAK4 (0.67) PAK4NAMPTPAK1HRH3GPR183
SCHEMBL18325827 0.91 PAK4 (0.69) PAK4NAMPTPAK1HRH3GPR183
SCHEMBL16347387 0.87 PAK4 (0.75) PAK4NAMPTPAK1HRH3GPR183
SCHEMBL16347388 0.87 PAK4 (0.75) PAK4NAMPTPAK1HRH3GPR183
SCHEMBL16345422 0.87 PAK4 (0.63) PAK4NAMPTPAK1HRH3GPR183
SCHEMBL16347385 0.87 PAK4 (0.79) PAK4NAMPTPAK1HRH3GPR183
SCHEMBL18317784 0.87 PAK4 (0.67) PAK4NAMPTPAK1HRH3GPR183
SCHEMBL18317403 0.87 PAK4 (0.63) PAK4NAMPTPAK1HRH3GPR183
SCHEMBL29611634 0.87 PAK4 (0.79) PAK4NAMPTPAK1HRH3GPR183

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085064-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF KARYOPHARM THERAPEUTICS INC (US) 2026-03-26 — — US disclosed
US-12331040-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2025-06-17 — — US disclosed
EP-3016946-B1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND PHARMACEUTICAL USES THEREOF KARYOPHARM THERAPEUTICS INC (US) 2022-10-12 — — EP disclosed
US-20210403459-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. 2021-12-30 — — US disclosed
US-11008309-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2021-05-18 — — US disclosed
US-20200102292-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. 2020-04-02 — — US disclosed
US-10399963-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2019-09-03 — — US disclosed
US-20180319779-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. 2018-11-08 — — US disclosed
US-9856241-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2018-01-02 — — US disclosed
US-20160368904-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. 2016-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368904-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF BCL6, MALT1, BTK PAK4 2007/4885NAMPT 1663/4885PAK1 3040/4885
US-20180319779-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF BCL6, MALT1, BTK PAK4 2260/4885NAMPT 1782/4885PAK1 3233/4885
US-12331040-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof BCL6, MALT1, BTK PAK4 2260/4885NAMPT 1782/4885PAK1 3233/4885
US-11008309-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof BCL6, MALT1, BTK PAK4 2260/4885NAMPT 1782/4885PAK1 3233/4885
US-10399963-B2 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof BCL6, MALT1, BTK PAK4 2260/4885NAMPT 1782/4885PAK1 3233/4885
US-20210403459-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF BCL6, MALT1, BTK PAK4 2260/4885NAMPT 1782/4885PAK1 3233/4885
US-20200102292-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF BCL6, MALT1, BTK PAK4 2260/4885NAMPT 1782/4885PAK1 3233/4885
US-20260085064-A1 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF BCL6, MALT1, BCL6B PAK4 4159/4885NAMPT 4695/4885PAK1 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback